Additionally, Peng et al. suggested that high levels of exosomal miR-320d, miR-320c, and miR-320b were associated with poor response to anti-PD-1 treatment in NSCLC patients, while exosomal miR-125b-5p was identified as a potential target for improving the effectiveness of anti-PD-1 therapy (Peng et al., 2020a). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.